# Epidarex Capital

Epidarex Capital is a Private Equity based in Bethesda, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Bethesda, United States
- **Region:** North America
- **Address:** 7910 Woodmont Avenue, Suite 1315, Bethesda, MD 20814, United States
- **Founded:** 2010
- **Assets under management:** Undisclosed
- **Website:** epidarex.com
- **LinkedIn:** https://www.linkedin.com/company/epidarex-capital

## Regulatory record

- **CRD number:** 307874
- **SEC file number:** 802-118468
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/307874

## About

Epidarex is a transatlantic venture capital firm led by a diverse team of early-stage investors building breakthrough life science companies in emerging hubs. They are trusted partners to founders and co-investors, using deep scientific and industry networks to create exceptional value and shared success. The firm builds extraordinary life science companies on both sides of the Atlantic.

## Sectors

- Biotechnology & Pharmaceuticals
- Medical Devices & Health Tech
- Drug Discovery & Development Platforms
- Neurodegenerative Disease
- Immuno-Oncology

## Offices

- Edinburgh, United Kingdom

## People

- A. Sinclair Dunlop — Managing Partner
- Kyparissia Sirinakis — Managing Partner
- Elizabeth Roper Ph.D. — Managing Partner
- Peter Finan Ph.D. — Managing Partner

## Questions

### Who runs investment decisions at Epidarex Capital?

Four managing partners — A. Sinclair Dunlop, Kyparissia Sirinakis, Elizabeth Roper, and Peter Finan — collectively lead investment decisions. They are supported by two additional Partners, a Venture Partner, and a Principal. The team's backgrounds bridge academic science, pharma R&D, and early-stage venture operating experience.

### How does Epidarex source deal flow?

Epidarex relies on a transatlantic network that interfaces directly with technology transfer offices at research universities in the UK and US mid-Atlantic. The firm focuses on institutions outside the traditional Boston–San Francisco biotech corridor. This position, combined with scientific advisory relationships, allows it to originate proprietary, often pre-formation, spin-out opportunities.

### What does Epidarex's portfolio exit history look like?

The firm has recorded trade sales to strategic acquirers: Harpoon Medical was acquired by Edwards Lifesciences in December 2017, Confluence Life Sciences was acquired by Aclaris Therapeutics in August 2017, and SIRAKOSS was acquired in November 2020. Apellis Pharmaceuticals reached a public listing on NASDAQ.

### How is the firm organized across its two offices?

Epidarex operates a dual-structure with an investment team split between Bethesda, Maryland and Edinburgh, Scotland. The US office primarily covers mid-Atlantic and Southeastern university spin-outs, while the UK office covers Scottish and English university ecosystems. The two teams share a common investment committee and portfolio management framework.

### Which sectors does Epidarex avoid?

Epidarex concentrates exclusively on life sciences — biotechnology, pharmaceuticals, medical devices, and health technology. It does not invest in non-healthcare sectors, digital health outside device-regulated pathways, or service-based healthcare businesses. Its negative screen excludes agricultural biotech and industrial biosciences.

### What is Epidarex's posture on co-investment alongside external GPs?

Epidarex welcomes co-investors and regularly builds syndicates that include top-tier life science venture funds for later-stage follow-on rounds. The firm's model is to de-risk the science with initial capital, then bring in larger funds for Series B and beyond, often retaining board seats and pro-rata rights.

## Related profiles

- [EPIC Ventures](https://altss.com/profile/epic-ventures)
- [Epilog Partners](https://altss.com/profile/epilog-partners-lp)

---

Last updated: 2026-08-11T15:06:42.396Z

Canonical page: https://altss.com/profile/epidarex-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology